Literature DB >> 11533003

CMY-2-producing Salmonella enterica, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis and Escherichia coli strains isolated in Spain (October 1999-December 2000).

F Navarro1, E Perez-Trallero, J M Marimon, R Aliaga, M Gomariz, B Mirelis.   

Abstract

CMY-2 plasmid-mediated AmpC beta-lactamase (CMY-2) was detected in 21 isolates from two hospitals located in different geographical regions of Spain between October 1999 and December 2000. The isolates comprised two Salmonella enterica serovars (Mikawasima and Montevideo), 16 Escherichia coli, one Klebsiella pneumoniae, one Klebsiella oxytoca and one Proteus mirabilis. In addition to the expected resistance to beta-lactams, including extended-spectrum cephalosporins and cefoxitin, all isolates showed a broad spectrum of associated resistance. All were resistant to sulfamethoxazole, chloramphenicol, tetracycline and streptomycin, and all but two were also resistant to gentamicin. Five isolates were studied in detail and all transferred CMY-2 and other resistance determinants by conjugation. Genomic DNA restriction pattern analysis of the E. coli isolates excluded the dissemination of a single clone. To the best of our knowledge this is the first time that CMY-2 has been detected in P. mirabilis, K. oxytoca and S. enterica serovars Mikawasima and Montevideo. It is also the first time that CMY-2 has been described in Spain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11533003     DOI: 10.1093/jac/48.3.383

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant beta-lactamases at a University Hospital in Barcelona, Spain, over a 3-year period.

Authors:  Elisenda Miró; Ferran Navarro; Beatriz Mirelis; Montserrat Sabaté; Alba Rivera; Pere Coll; Guillem Prats
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

2.  Multiple outbreaks of nosocomial salmonellosis in Russia and Belarus caused by a single clone of Salmonella enterica serovar Typhimurium producing an extended-spectrum beta-lactamase.

Authors:  M Edelstein; M Pimkin; T Dmitrachenko; V Semenov; N Kozlova; D Gladin; A Baraniak; L Stratchounski
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

3.  Evaluation of four phenotypic methods to detect plasmid-mediated AmpC β-lactamases in clinical isolates.

Authors:  M J Gude; C Seral; Y Sáenz; M González-Domínguez; C Torres; F J Castillo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-01-26       Impact factor: 3.267

4.  Escherichia coli producing an ACC-1 class C beta-lactamase isolated in Barcelona, Spain.

Authors:  Elisenda Miró; Beatriz Mirelis; Ferran Navarro; Lurdes Matas; Montserrat Giménez; Cinta Rabaza
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

5.  CMY-16, a novel acquired AmpC-type beta-lactamase of the CMY/LAT lineage in multifocal monophyletic isolates of Proteus mirabilis from northern Italy.

Authors:  Marco M D'Andrea; Elisabetta Nucleo; Francesco Luzzaro; Tommaso Giani; Roberta Migliavacca; Francesca Vailati; Vesselina Kroumova; Laura Pagani; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

6.  Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain.

Authors:  E Miró; J Agüero; M N Larrosa; A Fernández; M C Conejo; G Bou; J J González-López; N Lara; L Martínez-Martínez; A Oliver; B Aracil; J Oteo; A Pascual; J Rodríguez-Baño; L Zamorano; F Navarro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-09-07       Impact factor: 3.267

7.  Characterization of CTX-M-140, a Variant of CTX-M-14 Extended-Spectrum β-Lactamase with Decreased Cephalosporin Hydrolytic Activity, from Cephalosporin-Resistant Proteus mirabilis.

Authors:  Guo-Bao Tian; Yi-Qi Jiang; Ying-Min Huang; Yun Qin; Lian-Qiang Feng; Xue-Fei Zhang; Hong-Yu Li; Lan-Lan Zhong; Kun-Jiao Zeng; Sandip Patil; Yong Xing; Xi Huang
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

8.  Molecular epidemiology and characterization of plasmid-encoded beta-lactamases produced by Tunisian clinical isolates of Salmonella enterica serotype Mbandaka resistant to broad-spectrum cephalosporins.

Authors:  Abdoulaye Makanera; Guillaume Arlet; Valérie Gautier; Mohamed Manai
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

9.  Characterization of multidrug-resistant Escherichia coli isolates associated with nosocomial infections in dogs.

Authors:  Susan Sanchez; M A McCrackin Stevenson; Charlene R Hudson; Marie Maier; Tameka Buffington; Quyen Dam; John J Maurer
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

10.  Ceftriaxone-resistant salmonella enterica serotype Newport, France.

Authors:  Svetlana Egorova; Mohammed Timinouni; Marie Demartin; Sophie A Granier; Jean M Whichard; Vartul Sangal; Laëtitia Fabre; Aurélia Delauné; Maria Pardos; Yves Millemann; Emmanuelle Espié; Mark Achtman; Patrick A D Grimont; François-Xavier Weill
Journal:  Emerg Infect Dis       Date:  2008-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.